000 02528 a2200781 4500
005 20250517211906.0
264 0 _c20180517
008 201805s 0 0 eng d
022 _a1533-4406
024 7 _a10.1056/NEJMoa1802357
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aEggermont, Alexander M M
245 0 0 _aAdjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
_h[electronic resource]
260 _bThe New England journal of medicine
_cMay 2018
300 _a1789-1801 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
650 0 4 _aAdjuvants, Immunologic
_xadverse effects
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadverse effects
650 0 4 _aB7-H1 Antigen
_xanalysis
650 0 4 _aDisease-Free Survival
650 0 4 _aDouble-Blind Method
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aInfusions, Intravenous
650 0 4 _aIntention to Treat Analysis
650 0 4 _aKaplan-Meier Estimate
650 0 4 _aMale
650 0 4 _aMelanoma
_xdrug therapy
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Recurrence, Local
650 0 4 _aNeoplasm Staging
650 0 4 _aQuality of Life
650 0 4 _aSkin Neoplasms
_xdrug therapy
650 0 4 _aSurvival Rate
700 1 _aBlank, Christian U
700 1 _aMandala, Mario
700 1 _aLong, Georgina V
700 1 _aAtkinson, Victoria
700 1 _aDalle, Stéphane
700 1 _aHaydon, Andrew
700 1 _aLichinitser, Mikhail
700 1 _aKhattak, Adnan
700 1 _aCarlino, Matteo S
700 1 _aSandhu, Shahneen
700 1 _aLarkin, James
700 1 _aPuig, Susana
700 1 _aAscierto, Paolo A
700 1 _aRutkowski, Piotr
700 1 _aSchadendorf, Dirk
700 1 _aKoornstra, Rutger
700 1 _aHernandez-Aya, Leonel
700 1 _aMaio, Michele
700 1 _avan den Eertwegh, Alfonsus J M
700 1 _aGrob, Jean-Jacques
700 1 _aGutzmer, Ralf
700 1 _aJamal, Rahima
700 1 _aLorigan, Paul
700 1 _aIbrahim, Nageatte
700 1 _aMarreaud, Sandrine
700 1 _avan Akkooi, Alexander C J
700 1 _aSuciu, Stefan
700 1 _aRobert, Caroline
773 0 _tThe New England journal of medicine
_gvol. 378
_gno. 19
_gp. 1789-1801
856 4 0 _uhttps://doi.org/10.1056/NEJMoa1802357
_zAvailable from publisher's website
999 _c28290388
_d28290388